- Home
- BRTX vs CRIS Comparison
BRTX vs CRIS Comparison
Compare BRTX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- CRIS
- Stock Information
- Founded
- BRTX 1997
- CRIS 2000
- Country
- BRTX United States
- CRIS United States
- Employees
- BRTX N/A
- CRIS N/A
- Industry
- BRTX Managed Health Care
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRTX Health Care
- CRIS Health Care
- Exchange
- BRTX Nasdaq
- CRIS Nasdaq
- Market Cap
- BRTX 12.2M
- CRIS 13.5M
- IPO Year
- BRTX N/A
- CRIS 2000
- Fundamental
- Price
- BRTX $1.71
- CRIS $1.63
- Analyst Decision
- BRTX Strong Buy
- CRIS Strong Buy
- Analyst Count
- BRTX 1
- CRIS 3
- Target Price
- BRTX $18.00
- CRIS $21.00
- AVG Volume (30 Days)
- BRTX 34.3K
- CRIS 105.6K
- Earning Date
- BRTX 05-13-2025
- CRIS 05-06-2025
- Dividend Yield
- BRTX N/A
- CRIS N/A
- EPS Growth
- BRTX N/A
- CRIS N/A
- EPS
- BRTX N/A
- CRIS N/A
- Revenue
- BRTX $401,000.00
- CRIS $10,908,000.00
- Revenue This Year
- BRTX $446.88
- CRIS $2.33
- Revenue Next Year
- BRTX $39.53
- CRIS $9.78
- P/E Ratio
- BRTX N/A
- CRIS N/A
- Revenue Growth
- BRTX 175.03
- CRIS 8.83
- 52 Week Low
- BRTX $1.03
- CRIS $1.02
- 52 Week High
- BRTX $2.55
- CRIS $16.99
- Technical
- Relative Strength Index (RSI)
- BRTX 46.37
- CRIS 45.07
- Support Level
- BRTX $1.64
- CRIS $1.06
- Resistance Level
- BRTX $1.78
- CRIS $1.70
- Average True Range (ATR)
- BRTX 0.10
- CRIS 0.14
- MACD
- BRTX -0.01
- CRIS 0.09
- Stochastic Oscillator
- BRTX 42.82
- CRIS 89.71
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.